Author Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We appreciate Dr. Lancaster's comments on our article.1 Indeed, the co-occurrence of MOG- or aquaporin-4-(AQP4) antibodies with anti-NMDAR encephalitis was associated with symptoms of this encephalitis, accompanied by a history or MRI features of a demyelinating disease. However, the co-occurrence of anti-NMDAR encephalitis with other neuronal antibodies was associated with symptoms of this encephalitis and clinical or MRI features of the associated antibody—e.g., medial temporal lobe MRI changes with AMPAR-antibodies or cortical-subcortical FLAIR MRI abnormalities with GABAaR-antibodies. Patients with an additional neuronal surface antibody had a worse prognosis than those with isolated anti-NMDAR encephalitis or with a concurrent glial antibody. Our experience with GFAP-antibodies suggests that the syndrome-specificity of these antibodies is less clear. In our study, GFAP-antibodies did not confer any additional clinical or radiologic features to anti-NMDAR encephalitis. Moreover, the meningoencephalomyelitis with linear perivascular enhancement that has been considered characteristic of GFAP-antibodies can also occur without these antibodies.2 If a patient with encephalitis and CSF NMDAR-antibodies develops a syndrome atypical for anti-NMDAR encephalitis, one should be concerned for (1) a potential laboratory error (e.g., the NMDAR-antibody test was falsely positive) or (2) that the syndrome represents a manifestation of 2 disorders with concurrent autoantibodies.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.